ArticleJournal of the American Society for Mass Spectrometry2025
Online Coupling of Asymmetrical Flow Field-Flow Fractionation with Native Mass Spectrometry for Monoclonal Antibody Characterization.
Article in Journal of the American Society for Mass Spectrometry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Integration of Asymmetrical Flow Field-Flow Fractionation (AF4) with online native mass spectrometry (MS) is an attractive concept that offers significant value for the analytical characterization of protein therapeutics. Its execution, however, is challenged by the incompatibility of mobile phase components and the difficulties of achieving sensitive MS detection without compromising the separation efficiency. Herein, we describe in detail the successful coupling of a commercial AF4 instrument with online native MS detection. By optimizing the operational conditions of AF4 using ammonium acetate-based mobile phases and fine-tuning the interface configurations, the established AF4-MS platform achieved uncompromised separation performance while enabling sensitive online native MS measurements. The feasibility of the method for studying protein analytes was first demonstrated by analyzing a protein mixture sample (17 kDa to 660 kDa), followed by size variant characterization of the NISTmAb. The AF4-MS method was subsequently compared with native SEC-MS using both protein mixture and mAb samples, highlighting their complementarity as size-based separation techniques and showcasing the quantitative advantages of AF4-MS. Applications of AF4-MS in supporting therapeutic mAb development were demonstrated using two case studies, including heterodimer quantitation in a coformulated mAb cocktail sample and antibody-antigen binding stoichiometry characterization. This developed AF4-MS method is easily implementable and could be a valuable addition to our analytical toolbox to support therapeutic mAb development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.